Discover ZEISS MyoEase, a new-generation upgrade building on MyoVision Kids, with fusion-defocus technology. Coming soon to Malaya Optical Malaysia.
ZEISS MyoEase Malaysia: A New-Generation Upgrade in Myopia Management for Children
Discover how ZEISS MyoEase builds on earlier ZEISS MyoVision Kids technology, its new fusion-defocus design, clinical research and what Malaysian parents should know.
When your child’s spectacle prescription increases year after year, it is natural to wonder whether there is more you can do than simply replace their glasses.
Perhaps your child started with −1.00D and now needs −2.00D. Perhaps they struggle to see the classroom board or frequently move closer to the television.
These changes may be signs of progressing myopia, commonly known as short-sightedness.
Today, specialised spectacle lenses can do more than correct blurred distance vision. They can also provide optical signals designed to help slow myopia progression during childhood.
One of the newer developments is ZEISS MyoEase, a new-generation myopia-management spectacle lens that builds on ZEISS’s earlier innovations, including MyoVision Kids.
Featuring a fusion design that combines simultaneous myopic defocus and peripheral defocus management, ZEISS MyoEase introduces a more integrated optical approach, supported by clinical research presented in 2026.
ZEISS MyoEase is coming soon to Malaya Optical Malaysia, with planned availability at our four branches in Kuala Lumpur, Petaling Jaya, Subang Jaya and Puchong.
But how does it work? What makes it different from older ZEISS lenses? And how does it compare with ZEISS MyoCare, HOYA MiYOSMART and Essilor Stellest?
Here is what Malaysian parents should know.
What Is ZEISS MyoEase?
ZEISS MyoEase is a specialised spectacle lens designed to correct childhood myopia while providing optical signals intended to slow the progression of short-sightedness.
Unlike ordinary single-vision spectacle lenses, which primarily correct blurred vision, MyoEase incorporates additional optical structures designed for myopia management.
Its technology combines two approaches:
- Simultaneous myopic defocus, which provides specialised optical signals alongside normal vision correction.
- Peripheral defocus management, which modifies how light is focused toward the peripheral regions of the visual field.
ZEISS combines these approaches in what it describes as a fusion design.
MyoEase is worn like ordinary spectacles. Children do not need to insert contact lenses, sleep with lenses on their eyes or follow a contact lens cleaning routine.
However, MyoEase does not cure myopia or guarantee that progression will stop. Its purpose is to help slow progression, with individual outcomes varying between children.
From ZEISS MyoVision Kids to ZEISS MyoEase: A New Generation of Myopia Management
ZEISS has spent many years researching optical approaches to childhood myopia management.
Earlier technologies, including ZEISS MyoVision Kids, explored the role of peripheral defocus in influencing eye growth.
These designs represented an important stage in the development of spectacle-based myopia management.
Today, ZEISS continues to build on that foundation.
ZEISS MyoEase represents a new-generation technological upgrade, introducing a fusion design that combines simultaneous myopic defocus and peripheral defocus management.
While earlier MyoVision designs focused on peripheral optical strategies, MyoEase incorporates additional treatment elements intended to provide myopic-defocus signals alongside peripheral power management.
This evolution reflects ZEISS’s continuing research into how spectacle lenses can provide clear vision while helping manage excessive eye elongation.
For Malaysian parents, MyoEase offers a newer optical approach supported by clinical research into refractive progression and axial-length changes.
ZEISS MyoVision Kids vs ZEISS MyoEase
| Feature | Earlier ZEISS MyoVision Technology | ZEISS MyoEase |
| Primary purpose | Correct vision and help manage childhood myopia | Correct vision and help manage childhood myopia |
| Main optical approach | Peripheral defocus management | Simultaneous and peripheral defocus |
| Design generation | Earlier ZEISS myopia-management technology | Newer fusion-defocus technology |
| Treatment structure | Earlier peripheral optical designs | Central clear zone with annular treatment structures and peripheral power progression |
| Clinical evidence | Research involving earlier MyoVision designs | Randomized 12-month crossover clinical trial |
| Main objective | Help manage progression | Help manage refractive progression and axial elongation |
ZEISS has developed different MyoVision-family designs over time. The table explains the broad technological evolution rather than implying that every historical MyoVision product has identical specifications.
Does Newer Technology Automatically Mean Better Myopia Control?
Not necessarily.
A newer optical design may introduce additional features or a different mechanism, but that does not automatically prove superior clinical performance.
The most useful evidence comes from studies measuring changes in prescription and axial length.
This is why we should evaluate ZEISS MyoEase based on its own clinical findings rather than simply describing it as better because it is newer.
Why Is Childhood Myopia Progression a Concern?
Myopia occurs when distant light focuses in front of the retina rather than directly on it.
In many children, this happens because the eye grows too long relative to its focusing power.
As the eye elongates, the child’s prescription may become increasingly negative.
For example, a child might progress from −1.00D to −2.00D and later to −3.00D.
These changes are not identical for every child. Some progress slowly, while others experience more rapid changes.
Higher levels of myopia are associated with increased lifetime risks of certain eye conditions, including myopic maculopathy, retinal detachment and glaucoma.
This is why managing myopia during childhood is increasingly important.
Correcting Myopia vs Managing Myopia
Conventional single-vision spectacles primarily correct blurred distance vision.
Myopia-management spectacles aim to provide clear vision while delivering additional optical signals intended to help slow excessive eye growth.
ZEISS MyoEase belongs to this second category.
How Does ZEISS MyoEase Technology Work?
To understand MyoEase, imagine a spectacle lens with different optical areas.
The central region provides the child’s normal prescription.
Surrounding regions incorporate specialised optical structures designed to produce myopic-defocus signals.
ZEISS MyoEase combines two approaches in one lens.
1. Simultaneous Myopic Defocus
Myopic defocus refers to an optical condition in which some light focuses in front of the retina.
Specialised myopia-management lenses are designed to introduce this signal while still correcting the child’s distance vision.
Researchers believe that appropriately designed myopic-defocus signals can help reduce excessive axial elongation.
This principle is used in several modern spectacle-lens technologies, although manufacturers achieve it through different optical structures.
2. Peripheral Defocus Management
Peripheral defocus concerns how light is focused away from the central line of sight.
Earlier ZEISS myopia-management designs investigated whether changing peripheral retinal focus could influence eye growth.
MyoEase builds on this area of optical research by incorporating peripheral power management alongside its simultaneous-defocus treatment structures.
3. ZEISS MyoEase Fusion Design
The MyoEase lens evaluated in ZEISS’s 2026 clinical research incorporates:
- A 7 mm central clear zone
- Four annular cylindrical treatment rings
- Approximately +4.00D mean surface power in the annular treatment structures
- A treatment region extending approximately 13 mm from the lens centre
- A peripheral back-surface power progression reaching up to +1.50D
These are optical design specifications, not additional prescription powers applied uniformly to the child’s vision.
The child’s main prescription remains appropriately corrected.
The specialised zones provide the additional optical structures intended for myopia management.
The key innovation is the combination of simultaneous and peripheral defocus in one spectacle lens design.
What Does the Clinical Research Say About ZEISS MyoEase?
ZEISS presented clinical findings for MyoEase at the 2026 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting.
The research evaluated whether MyoEase could slow childhood myopia progression compared with conventional single-vision spectacle lenses.
How Was the Study Conducted?
The randomized, double-masked crossover trial involved 120 Chinese children aged 6–12 years.
Participants had starting spherical equivalent prescriptions between approximately −0.75D and −5.00D.
The study lasted 12 months and involved two treatment periods.
During the first six months:
- 60 children wore ZEISS MyoEase study lenses.
- 60 children wore conventional single-vision lenses.
After six months, the groups switched treatments.
Children initially wearing MyoEase changed to single-vision spectacles, while those wearing single-vision spectacles changed to MyoEase.
This allowed researchers to compare progression during the two different lens-wearing conditions.
What Did Researchers Measure?
Two key measurements were evaluated.
Spherical equivalent refraction
This measures changes in the child’s prescription, expressed in dioptres (D).
Axial length
This measures the length of the eye from front to back, expressed in millimetres.
Both measurements are important because myopia progression is not only about changing spectacle power. It is also closely associated with excessive eye elongation.
ZEISS MyoEase Clinical Results Explained
The study found significantly slower myopia progression during periods when children wore MyoEase compared with periods when they wore conventional single-vision spectacles.
| Clinical Outcome | First 6 Months | Second 6 Months |
| Reduction in refractive progression compared with single vision | 0.32D | 0.25D |
| Reduction in axial elongation compared with single vision | 0.12 mm | 0.11 mm |
| Statistical significance | P less than 0.001 | P less than 0.001 |
These figures describe differences between treatment conditions, not the absolute amount of progression experienced by every child.
For example, a 0.12 mm reduction in axial elongation means that average eye growth was 0.12 mm less during the MyoEase treatment condition than during the corresponding single-vision comparison.
It does not mean that the eye became shorter.
Average Treatment Differences
Across the two treatment periods, ZEISS reported average differences of approximately:
0.28D less refractive progression per six-month treatment period
and
0.12 mm less axial elongation per six-month treatment period
compared with single-vision spectacles.
These results are encouraging because they demonstrate measurable differences in both prescription progression and eye growth.
However, the findings represent group averages. Individual treatment responses may differ.
Did 8 Out of 10 Children Respond to ZEISS MyoEase?
ZEISS reported that approximately eight out of ten children showed slower myopia progression during MyoEase wear compared with single-vision lens wear.
The reported proportion increased to nearly nine out of ten among children wearing MyoEase for at least 12 hours daily.
This suggests that consistent wear may be important to achieving the intended treatment effect.
However, these figures do not mean that MyoEase stops myopia in 80–90% of children.
They also do not mean that every child experiences an 80–90% reduction in progression.
The findings indicate that a substantial proportion of study participants demonstrated a slower progression rate under the MyoEase treatment condition.
What Happens If a Child Stops Wearing MyoEase?
The crossover study also provided information about what happened when children changed from MyoEase back to ordinary single-vision spectacles.
ZEISS reported no indication of a rebound effect during the observation period.
In other words, the researchers did not observe a clear acceleration beyond the comparison progression pattern after the children switched treatments.
This is encouraging, but it does not prove that rebound can never occur or establish the long-term effects of discontinuing MyoEase.
Longer-term studies would be valuable.
How Strong Is the Clinical Evidence?
The MyoEase study has several strengths.
It used randomized allocation, a double-masked design, a single-vision comparison and objective axial-length measurements.
Its crossover design also allowed researchers to examine treatment response under different lens conditions.
However, there are limitations.
The study involved 120 children from China, aged 6–12 years, within a defined prescription range.
Each treatment period lasted six months, so the trial does not establish the outcome of several consecutive years of uninterrupted MyoEase wear.
The research was reported within ZEISS’s clinical research programme, and further independent, longer-term studies would be useful.
The current evidence supports MyoEase as a promising myopia-management spectacle lens, but does not establish that it is superior to every competing lens design.
ZEISS MyoEase vs ZEISS MyoCare: What Is the Difference?
Although both are ZEISS myopia-management spectacle lenses, MyoEase and MyoCare use different optical technologies.
ZEISS MyoEase
MyoEase combines simultaneous myopic defocus and peripheral defocus management through its fusion design.
Its reported clinical evidence includes the 12-month randomized crossover study.
ZEISS MyoCare
ZEISS MyoCare uses C.A.R.E. technology — Cylindrical Annular Refractive Elements.
Its specialised optical elements are arranged in concentric rings around a central correction zone.
ZEISS also incorporates ClearFocus design to support vision through different parts of the lens.
MyoCare has a separate clinical research programme, including multi-year studies.
Comparison Table
| Feature | ZEISS MyoEase | ZEISS MyoCare |
| Technology | Fusion defocus design | C.A.R.E. |
| Main optical approach | Simultaneous and peripheral defocus | Cylindrical annular refractive elements |
| Central correction zone | Yes | Yes |
| Treatment design | Annular treatment structures and peripheral power progression | Concentric treatment elements alternating with correction zones |
| Clinical evidence | Randomized 12-month crossover trial | Multi-year, multicentre clinical research |
| Primary purpose | Slow childhood myopia progression | Slow childhood myopia progression |
Which ZEISS Lens Is Better?
There is currently insufficient direct comparative evidence to conclude that MyoEase is better than MyoCare for every child.
The two designs have different optical structures and clinical research histories.
The appropriate choice depends on the child’s prescription, progression, age, axial length, visual needs and clinical assessment.
How Does ZEISS MyoEase Compare With Other Myopia-Control Spectacle Lenses?
Several spectacle-lens technologies are available for childhood myopia management.
Although their purpose is similar, their optical designs differ.
| Lens | Technology | Optical Approach |
| ZEISS MyoEase | Fusion defocus design | Simultaneous and peripheral defocus |
| ZEISS MyoCare | C.A.R.E. | Cylindrical annular refractive elements |
| HOYA MiYOSMART | D.I.M.S. | Defocus Incorporated Multiple Segments |
| Essilor Stellest | H.A.L.T. | Highly Aspherical Lenslet Target |
| VisionXlab H.O.R.I. | Hexagon Optimized Reticular Integration | Integrated array of 540 hexagonal lenslets |
These technologies use different approaches to creating optical treatment signals.
Their clinical studies also differ in duration, participant characteristics and comparison methods.
For this reason, effectiveness percentages from different manufacturers should not be directly ranked without appropriate head-to-head clinical evidence.
At Malaya Optical, we believe myopia management should be selected according to the child’s individual needs rather than whichever lens technology is newest.
Advantages of ZEISS MyoEase
1. Spectacle-Based Management
Children can receive myopia management without inserting or removing contact lenses.
2. Newer Fusion-Defocus Technology
MyoEase combines simultaneous and peripheral defocus strategies within one lens design.
3. Supported by Randomized Clinical Research
Its clinical trial measured both refractive progression and axial elongation.
4. Clear Vision With a Myopia-Management Objective
The lens corrects the child’s prescription while providing its specialised treatment structures.
5. Practical for Everyday Activities
As a spectacle-based option, MyoEase may suit children who prefer glasses over contact lenses.
6. Can Be Monitored Through Ocular Biometry
Its effectiveness can be assessed as part of a structured myopia-management programme that monitors prescription and axial length.
Important Considerations Before Choosing ZEISS MyoEase
It does not cure myopia. The objective is to slow progression.
Consistent wear is important. The treatment structures cannot provide their intended optical signal while the spectacles are not being worn.
Individual responses vary. Some children may continue to experience progression.
Professional fitting matters. Appropriate frame selection, centration and positioning are important.
Adaptation may be necessary. Some children may need time to become accustomed to the specialised optical design.
Longer-term research is still developing. More studies will help clarify outcomes over several consecutive years.
Regular monitoring is essential. A myopia-management lens should be part of an ongoing clinical plan rather than a one-time purchase.
How Many Hours Should Children Wear ZEISS MyoEase?
The clinical research suggests that wearing time plays an important role in treatment response.
ZEISS reported a higher responder proportion among children who wore MyoEase for at least 12 hours per day.
This does not mean that 12 hours guarantees successful treatment.
Rather, it supports the importance of consistent daily wear.
Parents should follow the wearing schedule recommended by their child’s optometrist.
For many children, this means wearing their prescribed spectacles throughout normal waking activities.
Why Frame Fitting and Lens Positioning Matter
Myopia-management lenses contain specialised optical zones.
Their positioning relative to the child’s eyes can influence how the child looks through the intended correction and treatment areas.
A professional fitting should consider:
- Accurate prescription
- Pupillary distance
- Lens centration
- Frame size
- Bridge fit
- Frame stability
- Wearing position
- Comfort and adaptation
Children’s spectacles should also be checked periodically because frames can become loose or change position with everyday use.
A properly fitted frame supports both comfortable vision and appropriate use of the lens design.
Why Malaya Optical Measures Axial Length, Not Just Prescription
At Malaya Optical, myopia management involves more than checking whether a child’s spectacle prescription has increased.
Our optometrists use ocular biometry, including the ARK Biometer Combo, to monitor axial length.
Axial length measures the eye from front to back.
In childhood myopia, excessive axial elongation is an important part of progression.
Monitoring axial length over time helps us understand how the eye is growing and whether a management strategy is having the intended effect.
What We Monitor
| Measurement | Why It Matters |
| Refractive prescription | Tracks changes in short-sightedness |
| Axial length | Measures eye growth |
| Progression rate | Helps identify how quickly myopia is changing |
| Baseline measurements | Provides a reference for future reviews |
| Treatment response | Helps evaluate the management plan |
| Wearing habits | Helps interpret changes and treatment adherence |
Why Axial Length Matters for Parents
Imagine two children with the same spectacle prescription.
One child’s axial length is increasing relatively slowly.
The other’s eye is elongating much more rapidly.
If we only measure spectacle power, we may miss important differences in their progression patterns.
This is why axial-length monitoring is an important part of Malaya Optical’s myopia-management approach.
How Often Should a Child Be Reviewed?
Myopia management should involve ongoing follow-up.
A baseline assessment is important before beginning treatment.
Depending on the child’s age, prescription, progression and clinical needs, reviews may be scheduled approximately every three to six months, or at another interval recommended by the optometrist.
During follow-up, our optometrists can assess:
- Changes in prescription
- Axial-length measurements
- Rate of progression
- Spectacle fit
- Wearing habits
- Visual comfort
- Whether adjustments to the management plan are appropriate
The aim is to make decisions using the child’s actual clinical measurements.
Who May Be Suitable for ZEISS MyoEase?
MyoEase may be considered for children with progressing myopia who are suitable for spectacle-based management.
The published clinical study involved children aged 6–12 years with prescriptions between −0.75D and −5.00D.
However, these were study inclusion criteria, not necessarily the full approved prescribing range for Malaysia.
The child’s suitability should be assessed by an optometrist using the relevant Malaysian product indications.
Important considerations include age, prescription, previous progression, axial length, family history, astigmatism, lifestyle and the ability to wear spectacles consistently.
Myopia Management for Malaysian Schoolchildren
For many children in Malaysia, daily routines involve substantial near work.
School lessons, homework, tuition, digital learning and recreational screen use can mean long periods of close-up visual activity.
Children in urban areas such as Kuala Lumpur, Petaling Jaya, Subang Jaya and Puchong may also have limited opportunities for outdoor activities during busy school weeks.
However, myopia is influenced by several factors, including genetics, age and environmental exposure.
Screen use alone should not be described as the sole cause.
What Parents Can Do
Encourage regular outdoor activity when practical and safe.
Provide breaks during prolonged near work.
Encourage comfortable reading distances.
Ensure suitable lighting for study.
Schedule regular eye examinations.
Follow the recommended wearing and review schedule for prescribed myopia-management treatments.
These habits support healthy visual routines but do not replace appropriate clinical management when a child has progressing myopia.
Why Early Myopia Detection Matters
Children do not always realise that their distance vision is becoming blurry.
Parents or teachers may notice that a child:
- Squints to see the classroom board
- Moves closer to the television
- Holds objects unusually close
- Complains of blurred distance vision
- Experiences frequent prescription changes
Malaya Optical has participated in eye-screening programmes at both international and government schools.
These experiences reinforce the importance of identifying possible vision problems early.
School screening can help identify children who need further assessment, but it does not replace a comprehensive eye examination or myopia-management evaluation.
ZEISS MyoEase vs Ortho-K, Soft Contact Lenses and Atropine
Spectacle lenses are one of several approaches to childhood myopia management.
| Treatment | When Used | Main Consideration |
| ZEISS MyoEase | Daytime spectacle wear | No contact lens handling |
| Orthokeratology | Overnight contact lens wear | Requires careful hygiene and fitting |
| Soft myopia-management contact lenses | Daytime contact lens wear | Requires contact lens handling |
| Low-dose atropine | As medically prescribed | Requires appropriate medical prescribing and monitoring |
There is no single treatment that is suitable for every child.
Some families prefer spectacles because they are familiar and do not require contact lens handling.
Others may benefit from orthokeratology, soft myopia-management contact lenses or medical co-management.
At Malaya Optical, we assess the child’s individual needs and discuss suitable management options with parents.
Frequently Asked Questions About ZEISS MyoEase
What is ZEISS MyoEase?
ZEISS MyoEase is a myopia-management spectacle lens designed to correct short-sightedness while providing optical signals intended to help slow progression.
Is ZEISS MyoEase an upgrade from MyoVision Kids?
MyoEase represents a newer generation of ZEISS myopia-management technology, building on earlier developments such as MyoVision Kids. It introduces a fusion design combining simultaneous and peripheral defocus.
What technology does ZEISS MyoEase use?
MyoEase uses a fusion-defocus design incorporating annular treatment structures and peripheral power management.
Is ZEISS MyoEase the same as ZEISS MyoCare?
No. MyoEase uses a fusion-defocus approach, while MyoCare uses C.A.R.E. technology.
Is MyoEase better than MyoCare?
There is insufficient direct comparative evidence to establish that MyoEase is better for every child. The appropriate choice depends on clinical assessment.
How effective is ZEISS MyoEase?
In a randomized crossover study involving 120 children, MyoEase significantly slowed refractive progression and axial elongation compared with conventional single-vision lenses during the treatment periods.
Does MyoEase stop myopia completely?
No. MyoEase aims to slow progression, but it does not guarantee that progression will stop.
Can MyoEase cure myopia?
No. It corrects the child’s existing refractive error and is designed to help manage further progression.
Is MyoEase suitable for young children?
It may be suitable for some children with progressing myopia, depending on their age, prescription, clinical findings and approved product indications.
How long should my child wear MyoEase each day?
Consistent wear is important. ZEISS reported higher responder proportions among children wearing MyoEase for at least 12 hours daily. Follow your optometrist’s individual recommendation.
Does my child still need regular eye examinations?
Yes. Ongoing monitoring of prescription, axial length, progression and spectacle fit is important.
Is MyoEase better than MiYOSMART or Stellest?
There is insufficient direct head-to-head evidence to establish that MyoEase is superior to these technologies for every child.
Can my child switch from ordinary spectacles to MyoEase?
Potentially, yes. A comprehensive assessment is recommended to determine suitability.
Where can I get ZEISS MyoEase in Malaysia?
ZEISS MyoEase is coming soon to Malaya Optical Malaysia, with planned availability at all four branches.
ZEISS MyoEase Is Coming Soon to Malaya Optical Malaysia
Malaya Optical has been caring for the visual needs of Malaysian families since 1957.
Our approach to childhood myopia management combines comprehensive eye examinations, clinical measurements, suitable optical technologies and ongoing monitoring.
ZEISS MyoEase will soon join our range of myopia-management spectacle lens options.
Planned availability includes:
- Malaya Optical Jalan Imbi — Kuala Lumpur
- Malaya Optical Damansara Uptown — Petaling Jaya
- Malaya Optical SS15 — Subang Jaya
- Malaya Optical Bandar Puteri — Puchong
MyoEase will provide another option for families considering spectacle-based myopia management.
Our optometrists will continue to assess each child’s individual needs rather than recommend a lens based solely on its brand or generation.
Book a Children’s Myopia Assessment
If your child’s spectacle prescription continues to increase, a comprehensive myopia assessment can help determine the next step.
At Malaya Optical, our optometrists can evaluate prescription changes, axial length, progression history and visual needs before discussing appropriate management options.
Book an appointment: https://book.malayaoptical.com
Interested in ZEISS MyoEase?
Although ZEISS MyoEase is not yet available at our branches, parents are welcome to enquire about its upcoming availability and discuss whether it may be appropriate for their child.
Clear vision matters today. Managing myopia progression matters for the years ahead.
Disclaimer: This article is for educational purposes and does not replace a comprehensive eye examination or individual professional advice. Myopia-management outcomes vary between children. Product availability, prescription ranges, approved age indications and final Malaysian specifications should be confirmed before prescribing.
Research References
- ZEISS Vision Care. Clinical Efficacy and Patient Response Dynamics of ZEISS MyoEase Lenses: A Comprehensive 12-Month Review. 2026.
https://www.zeiss.com/myopia/en/articles–insights/clinical-efficacy-and-patient-response-dynamics-of-zeiss-myoease-lenses.html - ZEISS Vision Care. ZEISS to Present New Clinical Study Results at ARVO 2026.
https://www.zeiss.com/vision-care/en/newsroom/news/2026/zeiss-to-present-new-clinical-study-results-at-arvo-2026-.html - ZEISS Malaysia. ZEISS Myopia Management Lenses.
https://www.zeiss.com.my/vision-care/need-new-lenses/myopia-management-lenses.html - ZEISS Malaysia. ZEISS MyoCare Lens Portfolio.
https://www.zeiss.com.my/vision-care/eye-care-professionals/lenses/lenses-for-every-need/lenses-to-manage-myopia-progression-in-children.html